摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-phenyl-8-(4-(pyrrolidin-1-ylmethyl)phenyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one | 1207455-39-7

中文名称
——
中文别名
——
英文名称
9-phenyl-8-(4-(pyrrolidin-1-ylmethyl)phenyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one
英文别名
9-Phenyl-8-(4-(pyrrolidin-1-ylmethyl)phenyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one;12-phenyl-11-[4-(pyrrolidin-1-ylmethyl)phenyl]-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one
9-phenyl-8-(4-(pyrrolidin-1-ylmethyl)phenyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one化学式
CAS
1207455-39-7
化学式
C27H26N4O
mdl
——
分子量
422.53
InChiKey
QRRXIQPVIZSLHQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    32
  • 可旋转键数:
    4
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.26
  • 拓扑面积:
    56.7
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    (E)-4-(4-(diethoxymethyl)benzylideneamino)isobenzofuran-1(3H)-one 在 盐酸一水合肼溶剂黄146 作用下, 以 二氯甲烷 为溶剂, 反应 17.0h, 生成 9-phenyl-8-(4-(pyrrolidin-1-ylmethyl)phenyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one
    参考文献:
    名称:
    [EN] METHODS OF USING DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE)POLYMERASE (PARP)
    [FR] MÉTHODES D'UTILISATION D'INHIBITEURS DIHYDROPYRIDOPHTHALAZINONIQUES DE LA POLY(ADP-RIBOSE) POLYMÉRASE (PARP)
    摘要:
    本文提供了治疗癌症的方法,包括联合给药拓扑异构酶抑制剂、替莫唑胺或铂类药物与式(I)或式(II)化合物的方法,其中取代基Y、Z、A、B、R1、R2、R3、R4和R5如本文所定义。
    公开号:
    WO2011130661A1
点击查看最新优质反应信息

文献信息

  • DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
    申请人:Wang Bing
    公开号:US20100035883A1
    公开(公告)日:2010-02-11
    A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.
    具有以下结构的化合物:其中取代基Y、Z、A、B、R1、R2、R3、R4和R5如本处所定义。本文提供了聚(ADP核糖)聚合酶活性的抑制剂。本文还描述了包括至少一种本文描述的化合物的药物组合物,以及使用本文描述的化合物或药物组合物治疗通过抑制PARP活性而改善的疾病、疾病和症状。
  • DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY
    申请人:Chu Daniel
    公开号:US20110190288A1
    公开(公告)日:2011-08-04
    A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.
    化合物具有以下公式(I)和公式(II)所示的结构: 其中,取代基Y、Z、A、B、R1、R2、R3、R4和R5的定义如本文所述。本文提供了聚(ADP-核糖)聚合酶活性抑制剂。本文还描述了包括至少一种本文所述化合物的制药组合物,以及使用本文所述的化合物或制药组合物治疗与PTEN缺陷相关的疾病、紊乱和病况,这些疾病、紊乱和病况通过抑制PARP活性得到改善。
  • Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
    申请人:BioMarin Pharmaceutical Inc.
    公开号:US08012976B2
    公开(公告)日:2011-09-06
    A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.
    具有以下结构式(I)和结构式(II)的化合物:其中,取代基Y、Z、A、B、R1、R2、R3、R4和R5的定义如本文所述。本文提供了一种poly(ADP-核糖)聚合酶活性抑制剂。本文还描述了包括至少一种上述化合物的制药组合物,并使用上述化合物或制药组合物来治疗通过抑制PARP活性改善的疾病、疾病和病况。
  • US8012976B2
    申请人:——
    公开号:US8012976B2
    公开(公告)日:2011-09-06
  • US8420650B2
    申请人:——
    公开号:US8420650B2
    公开(公告)日:2013-04-16
查看更多